Key facts
- This page summarizes Shanshan Xu's Form 4 filing for Bambusa Therapeutics, Inc..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 02 Nov 2026, 16:01.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Award
Additional SEC filing notes
Footnote F1
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean October 29, 2026.
Footnote F2
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F3
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2026 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the RSUs subject to the award shall vest upon the Administrator (as defined in the Issuer's 2026 Equity Incentive Plan) determining and certifying the achievement of the weighted average price of a share of the Issuer's common stock equals or exceeds $32 for any period of 30 consecutive trading days following April 1, 2027 and prior to April 1, 2030.
SEC remarks
Co-Founder, Chief Executive Officer, President, and Chairperson